Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in type 2 diabetes and obesity-related treatment pathways under brands such as Victoza and Saxenda. It is used for glycemic control and cardiovascular risk reduction in appropriate diabetes populations, and is also used for chronic weight management in obesity/overweight indications. U.S. FDA approval history for Victoza begins in 2010.
The global API market is projected to grow to USD 198.39 billion by 2030 from USD 144.20 billion in 2025, at a 6.6% CAGR. Oncology, rare disease and diabetes pipelines are key growth drivers.
New clinical evidence demonstrates that combining SGLT2 inhibitors with GLP-1 receptor agonists provides additive benefits for type 2 diabetes patients, while machine learning tools help personalize therapy selection.
New research reveals how GLP-1 receptor agonists promote pancreatic health through gene expression changes and interact bidirectionally with gut microbiome, while real-world users report unexpected lifestyle changes alongside weight loss.
A large study of over 600,000 U.S. veterans with type 2 diabetes found GLP-1 medications reduced the risk of developing substance use disorders by 14% and cut drug-related deaths by 50% in those with existing addiction.
A systematic review of 64 randomized clinical trials found GLP-1 receptor agonists produce greater weight loss in women than men, while the global market is projected to grow from $51.57 billion in 2026 to $112.62 billion by 2032.
Australian regulators confirmed counterfeit GLP-1 products contain no active ingredients, while U.S. authorities escalate enforcement against compounded weight-loss drugs as Novo Nordisk sues telehealth company Hims & Hers.
New target trial emulation study finds GLP-1 receptor agonists associated with lower heart failure hospitalization risk versus DPP-4 inhibitors and similar risk to SGLT-2 inhibitors in type 2 diabetes patients.
Novo Nordisk will reduce prices for Wegovy, Ozempic, and Rybelsus by up to 50% starting January 2027. Meanwhile, WADA investigates potential Olympic ban on weight loss drugs, and Brazil's Anvisa reports 65 suspected deaths linked to GLP-1 medications.
Triple-agonist drug retatrutide has demonstrated weight loss outcomes similar to bariatric surgery in Phase 3 trials. Research shows GLP-1 drugs work through brain-mediated appetite suppression and are effective even in genetic obesity.
Private prescriptions for GLP-1 weight-loss drugs in England are concentrated in affluent areas despite higher obesity rates in deprived regions. Online pharmacies face scrutiny for inadequate verification checks when dispensing these medications.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07244003 |
Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control |
RECRUITING | PHASE4 |
| NCT07225816 |
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) |
RECRUITING | PHASE1 |
| NCT07029009 |
Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY) |
RECRUITING | PHASE2 |
| NCT06818292 |
Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists |
COMPLETED | NA |
| NCT06501326 |
Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease |
RECRUITING | PHASE4 |
| NCT06438146 |
LIROH - Liraglutide for Obesity in HIV |
RECRUITING | PHASE4 |
| NCT06283641 |
Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan. |
COMPLETED | |
| NCT06099067 |
Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP) |
COMPLETED | |
| NCT05965908 |
Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome |
COMPLETED | PHASE3 |
| NCT05779644 |
Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus |
UNKNOWN | NA |
